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ABSTRACT
We investigated the effects of mTOR and MEK1/2 inhibition on tumor growth 
and the tumor microenvironment in immunogenic and poorly immunogenic models 
of murine oral cancer. In vitro, rapamycin and PD901 inhibited signaling through 
expected downstream targets, but only PD901 reduced viability and altered function 
of MOC cells. Following transplantation of MOC cells into immune-competent mice, 
effects on both cancer and infiltrating immune cells were characterized following 
rapamycin and/or PD901 treatment for 21 days. In vivo, both rapamycin and PD901 
inhibition reduced primary growth of established MOC tumors on treatment. Following 
withdrawal of PD901, rapid rebound of tumor growth limited survival, whereas 
durable tumor control was observed following rapamycin treatment in immunogenic 
MOC1 tumors despite more robust inhibition of oncogenic signaling by PD901. 
Characterization of the immune microenvironment revealed diminished infiltration and 
activation of antigen-specific CD8+ T-cells and other immune cells following PD901 
but not rapamycin in immunogenic tumors. Subsequent in vitro T-cell assays validated 
robust inhibition of T-cell expansion and activation following MEK inhibition compared 
to mTOR inhibition. CD8 cell depletion abrogated rapamycin-induced primary tumor 
growth inhibition in MOC1 mice. These data have critical implications in the design 
of combination targeted and immune therapies in oral cancer.
INTRODUCTION
Outcomes of patients diagnosed with advanced 
head and neck squamous cell carcinoma (HNSCC) remain 
poor despite advances in locoregional management. 
Human papillomavirus (HPV)-associated HNSCC, 
which represents 20% of all HNSCC, demonstrates good 
responses to standard anti-cancer therapies with disease-
specific survival rates of ≥ 80% [1]. Conversely, half 
or more of all patients diagnosed with advanced-stage 
carcinogen-associated HNSCC will die from their disease 
within 5 years. Further, current treatment strategies often 
functionally disable patients that do respond well to 
therapy and lead to long-term quality of life impairment 
[2]. Clearly, more efficacious treatment options are needed 
for this patient population.
Emerging data from The Cancer Genome Atlas 
(TCGA) has identified genomic changes associated with 
the development of HNSCC [3]. Alterations in EGFR, 
FGFR1/3, IGFR, PIK3CA or RAS genes are found in 60% 
of HPV-negative HNSCC and drive direct or cross-talk 
activation of the phosphoinositide 3-kinase/mammalian 
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target of rapamycin (PI3K/mTOR) and mitogen activated 
protein kinase kinase/extracellular related signal kinases 
1 and 2 (MEK/ERK1/2) pathways [4]. As such, therapeutic 
inhibition of these pathways with small molecule 
inhibitors in models of head and neck cancer have been 
extensively investigated [5–7].
Benefit versus toxicity from therapy targeting the 
PI3K/mTOR and MEK/ERK1/2 pathways alone or in 
combination is a concern [8]. Given the important role 
of these signaling pathways in a number of physiologic 
systems, targeted therapies can have both desirable, 
inhibitory effect on cancer cells as well as undesirable 
effects on other cell types. No where is this more evident 
than on cells of innate and adaptive immunity, where 
different targeted therapies may directly suppress a 
number of different stimulatory and effector functions 
[9]. The majority of pre-clinical investigation involves 
the use of xenograft models, which to do not allow the 
study of how systemic agents affect adaptive immunity 
activation. Recognition of how different anti-tumor agents 
affect immune cell function is critical given the interest 
in combining targeted and immune-activating anti-cancer 
therapies [10], but poorly studied.
The murine oral cancer (MOC) model is a syngeneic 
model that allows study of host anti-tumor immunity. 
Previous work has demonstrated that MOC1 cells, which 
exhibit a high genomic alteration rate, generate tumors 
with increased CD8 T-cell infiltration and increased 
interferon-γ (IFNγ), MHC class I and programmed death 
ligand 1 (PD-L1) expression compared to MOC2 tumors 
in immune-competent mice [11]. Similar to MOC1, 
roughly two-thirds of HNSCC tumors demonstrate 
a high degree of genomic alterations and increased 
immunoreactive infiltrates. Conversely, similar to MOC2, 
human HNSCCs include a subset of RAS mutant tumors 
with low frequency of genetic alterations and limited 
immunogenicity [3, 12, 13]. The effects of PI3K/mTOR 
and MAPK pathway targeting agents on anti-tumor 
immunity are of interest given the demonstrated activity of 
immune checkpoint inhibitors in HNSCC [12, 14] and the 
potential for enhanced patient responses with combining 
these immune-modulators with targeted therapies.
Here, we characterized the anti-tumor and immune 
effects of rapamycin, an FDA-approved inhibitor of 
mTOR signaling, and an investigational MEK1/2 inhibitor 
PD0325901 in these syngeneic MOC1 and 2 murine 
models of Ras-mutant oral cavity cancer. We validated 
on-target effects of these agents both in vitro and in vivo 
and the ability of both drugs to suppress primary tumor 
growth while on-treatment, yet demonstrated that MEK 
inhibition alone consistently resulted in measurable altered 
MOC cell viability and function with little effect following 
mTOR inhibition. Paradoxically, mTOR but not MEK 
inhibition resulted in durable tumor control following 
cessation of therapy in immunogenic MOC1 but not 
poorly immunogenic MOC2 tumors. We demonstrated 
that this differential response is not due to enhanced 
tumor cell-specific effects of in vivo mTOR inhibition but 
rather due to preservation of antigen-specific CD8 T-cell 
responses that are suppressed following MEK inhibition. 
We experimentally validate the relative preservation 
of T-cell expansion and activation following mTOR 
inhibition and significant suppression following MEK 
inhibition. Finally, we mechanistically demonstrated 
that in vivo tumor growth suppression following mTOR 
inhibition in vivo is CD8 cell dependent. These data have 
significant implications in the design of future experiments 
combing in these agents with immune-activating therapies.
RESULTS
MEK but not mTOR inhibition directly alters 
viability and function of MOC cells in vitro
As Murine Oral Cancer (MOC) cells carry activating 
Ras mutations secondary to DMBA-induced carcinogenesis, 
we hypothesized that MOC cells would demonstrate 
variable sensitivity to rapamycin and PD901 treatment in 
vitro. Inhibition of MEK with PD901 resulted in efficient 
MOC cell killing with IC50s in the low nanomolar range for 
both MOC1 and MOC2 (132 nM and 112 nM, respectively, 
nonlinear regression analysis, Fig 1A). Conversely, mTOR 
inhibition with rapamycin failed to reach an IC50 dose in 
either cell line despite treatment with concentrations as high 
as 20 μM, indicating that MEK but not mTOR inhibition is 
directly cytotoxic to MOC1 and 2 cells.
We next validated on-target effects of both PD901 
and rapamycin treatment in vitro via western blot analysis 
(Fig 1B). For these experiments, the IC50 dose of PD901, 
which falls within the serum concentration achieved in 
patients [15], was used. As no IC50 dose of rapamycin 
was achieved, a concentration of 1 μM was used for these 
experiments. Treatment with PD901 resulted in reduced 
phosphorylation of downstream ERK1/2 (T202/Y204) as 
expected, but also reduced phosphorylation of AKT (both 
residues) and S6K (S240/244) downstream of mTOR 
in MOC1 cells. Interestingly, MEK inhibition increased 
phosphorylation of AKT at the T308 residue and only 
modestly limited S6 phosphorylation in MOC2 cells, 
consistent with enhanced signaling though PI3K/PDK1 
[16]. Rapamycin treatment suppressed phosphorylation of 
S6K as expected, but enhanced cross-activation of ERK 
to a greater degree in MOC2 than MOC1. Rapamycin 
also reduced phosphorylation of AKT at residue S473, 
consistent with mTORC2 suppression, but increased AKT 
T308 phosphorylation in MOC2 > MOC1, suggesting 
enhanced PI3K signaling through release of mTOR/S6K 
mediated negative-feedback inhibition [17]. Neither drug 
appeared to alter phosphorylation of RelA/p65 in vitro. 
Together, the compensatory activation of ERK and 
AKT provide a potential explanation for the limited 
anti-proliferative effects of rapamycin observed in vitro. 
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Indeed, combination treatment induced significant 
suppression of both ERK and S6K phosphorylation. Thus, 
PD901 and rapamycin individually block phosphorylation 
of signaling proteins downstream of their expected targets, 
and observed compensatory activation of the untargeted 
pathway may be overcome with combination therapy.
HNSCC cells express angiogenic cytokines such 
as CXCL1 and VEGF downstream of PI3K and MAPK 
signaling [18, 19]. The production of both cytokines was 
significantly higher at baseline in MOC2 than MOC1 
cells (p < 0.001, Fig 1C). In MOC1 cells, PD901 but not 
rapamycin consistently inhibited expression of CXCL1 
and VEGF. In MOC2 cells, both rapamycin and PD901 
significantly reduced CXCL1 and VEGF expression. 
In MOC cells, expression of adhesion and stem cell 
marker CD44 is tightly linked to ERK1/2 signaling [20]. 
Treatment with PD901 significantly reduced CD44 cell 
surface expression on both MOC1 and MOC2 cells, 
whereas rapamycin enhanced CD44 expression on 
MOC2 cells following treatment (Fig 1D). To assess 
alterations in migratory capacity, an in vitro wounding 
assay was performed (Fig 1E). PD901 but not rapamycin 
inhibition consistently reduced MOC cell migratory 
capacity in both MOC1 and 2 cells. Taken together, these 
data indicate that while both PD901 and rapamycin are 
able to block signaling through their respective targets, 
cytotoxicity is induced, cytokine and CD44 expression 
is altered and cellular migration is reduced following 
MEK but not mTOR inhibition in vitro. The predominant 
dependence of these cellular features on MEK signaling 
Figure 1: In vitro characterization of the effects of MEK and mTOR inhibition on MOC1 and 2 cells. A. XTT assay data, 
following treatment with rapamycin or PD901 at the doses indicated for 48 hours. Results are representative of two independent experiments. 
B. western blot analysis of total and phospho-targets following treatment for 48 hours. Cells were treated with 1 μM rapamycin or 150 nM 
PD901 or both for 48 hours as indicated unless otherwise stated. Quantification of band density was normalized to actin. C. cytokine 
quantification via ELISA following treatment. Prior to ELISA, viable (trypan exclusion) cells were counted and cytokine levels were 
normalized to cell count to account for any drug-induced cytotoxicity. Combined results from two independent experiments are shown. 
D. flow cytometric analysis of CD44 expression following treatment. Nonviable cells were excluded from analysis via FSC/SCC gating 
and 7AAD staining (data not shown). Results representative of three independent experiments are shown. E. wounding assay following 
treatment. Representative MOC1 photomicrographs are 20x magnification, with yellow lines denoting baseline cell free region. Control 
consisted of equal volume of DMSO for all experiments. *p < 0.05, **p < 0.01, ***p < 0.001 for all experiments, analysis via one-way 
ANOVA with reference to control (DMSO treated) cells.
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is consistent with the Ras-mutant genotype of MOC 
cells.
Both MEK and mTOR inhibition significantly 
reduce MOC primary tumor growth in vivo
Anti-cancer therapies often demonstrate effects 
in the complex tumor microenvironment beyond what 
is observed in culture. Above, we established that 
MEK significantly alters MOC1 and 2 cell viability and 
function. Conversely, mTOR inhibition appears to have 
little direct effect on MOC cells. To assess the effect of 
MEK and mTOR inhibition in vivo, MOC1 and MOC2 
cells were transplanted into the flanks of immune-
competent C57BL/6 mice and treated with PD901 and 
rapamycin alone or in combination. Fig 2A demonstrates 
MOC1 and MOC2 tumors excised following 21 days of 
treatment with drug or control (MOC1 day 50, MOC2 
day 34), highlighting differences in tumor size and 
vascularity with treatment. In immunogenic MOC1 
tumors, treatment with either drug alone significantly 
reduced primary tumor growth (Fig 2B, graph and table). 
Since either drug alone had significant effects, combining 
PD901 and rapamycin did not significantly enhance 
primary growth suppression in MOC1. Conversely, the 
combination of drugs significantly reduced primary tumor 
growth over either drug alone in poorly immunogenic 
MOC2 tumors. MEK blockade alone inhibited primary 
tumor growth more than mTOR blockade alone in MOC2 
tumors, though the difference did not reach statistical 
significance. Combination rapamycin and PD901 was 
well tolerated with no treatment-associated weight loss 
Figure 2: Alteration of primary tumor growth following MEK and mTOR inhibition in vivo. A. Representative photographs 
of MOC1 (day 50) and MOC2 (day 34) tumor-bearing mice and corresponding excised tumors. B. Primary tumor growth curves for MOC1 
and MOC2 tumors with indicated 21-day treatment period. MOC cells were transplanted and allowed to form tumors with a volume of 
0.1 cm3 before initiation of treatment. Table reflects number of days after initiation of therapy needed to reach significant differences 
between growth curves, +p < 0.05, ++p < 0.01, +++p < 0.001 (parametric or non-parametric t-test for each time point). C. extended 
individual growth curves of tumor bearing mice plotting primary tumor growth after the completion of the treatment. Treatment period 
indicated on each plot. Extended growth data was derived from mice not euthanized for tissue at the end of the treatment period. All MOC2 
tumor-bearing mice reached end-point criteria, whereas several rapamycin and combo treated MOC1 mice were alive at the end of the 
experiment (100 days) and were euthanized before end-point criteria were reached. D. survival data for MOC1 and MOC2 tumor-bearing 
mice (*p < 0.05, **p < 0.01, ***p < 0.001, Log-Rank/Mantel-Cox test).
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while on treatment in either group, contrasted with MOC2 
control mice that began to lose weight due to tumor 
associated cachexia toward the end of the treatment period 
(Supplementary Fig S1). These data suggest that while 
active MEK inhibition suppresses the growth of primary 
MOC1 and 2 tumors as expected, mTOR inhibition alone 
results in significant primary tumor growth inhibition 
in immunogenic MOC1 tumors despite there being no 
evidence of direct MOC1 cell cytotoxicity following 
mTOR inhibition in vitro.
mTOR but not MEK inhibition induces a 
durable therapeutic tumor response in  
MOC tumors
Following completion of 21 days of treatment, mice 
not euthanized for tissue analysis were followed for post-
treatment growth kinetics and survival. In MOC2 tumor-
bearing mice, primary tumors grew rapidly following 
cessation of treatment with PD901 treated mice reaching 
euthanization criteria due to either primary tumor size 
(>2 cm diameter) or moribund status within one week 
(Figure 2C). MOC2 mice treated with rapamycin or 
combination demonstrated modest but statistically 
significant enhanced survival beyond control or PD901 
treated mice (Figure 2D). Similarly, MOC1 tumor-bearing 
mice treated with PD901 demonstrated aggressive tumor 
growth rebound following cessation of treatment with 
statistically significant but minimal prolonged survival 
compared to control. Interestingly, the majority of MOC1 
tumor-bearing mice treated with rapamycin alone or in 
combination with PD901 demonstrated durable primary 
growth suppression and survived to the end of the 
experiment (100 days). Combining PD901 with rapamycin 
appeared to attenuate the delayed growth and survival 
advantage over that observed with rapamycin alone. 
Again, despite having no direct cytotoxic effects in vitro, 
rapamycin appears to promote more durable primary 
tumor growth control and survival beyond that observed 
with PD901 in mice bearing RAS-mutant MOC tumors. 
Interestingly, this durable treatment effect of rapamycin is 
notably more pronounced in immunogenic MOC1 tumors 
than in poorly immunogenic MOC2 tumors.
MEK but not mTOR inhibition consistently 
results in decreased proliferation and induction 
of apoptosis in MOC tumors
To investigate mechanisms to explain the 
differences in response to therapy between MEK and 
mTOR inhibition in MOC tumor bearing mice, we 
wished to validate the on-target effects of PD901 and 
rapamycin treatment in vivo. Consistent with in vitro 
data, MEK inhibition with PD901 significantly reduced 
the phosphorylation of ERK and S6 in MOC1 and MOC2 
tumors (Fig 3A, 3B). Rapamycin treatment suppressed 
phosphorylation of S6 and either did not alter (MOC1) 
or enhanced phosphorylation of ERK (MOC2), similar 
to effects in vitro. Enhanced phosphorylation of ERK 
following rapamycin treatment in MOC2 tumors was 
suppressed when combined with PD901. High baseline 
tumor cell CD44 expression in MOC2 was significantly 
reduced with PD901 but enhanced (by mean fluorescence 
intensity, MFI) with rapamycin treatment (Fig 3C). Again, 
this enhancement was reversed with combination therapy. 
Cumulatively, the alterations in phospho-targets and CD44 
expression following treatment in vivo largely mirror 
those observed in vitro and suggest that both PD901 and 
rapamycin exert expected on-target effects on tumor cells 
in vivo and that compensatory activation of non-targeted 
pathways, which is pronounced in MOC2, can be reversed 
with combination therapy.
Functional consequences of MEK and mTOR 
inhibition were assessed by evaluating for tumor cell 
proliferation and apoptosis in vivo. Treatment with 
either drug alone significantly reduced proliferation 
measured via Ki67 staining in MOC1 tumors, whereas 
combination PD901 and rapamycin was needed to 
significantly decrease proliferation in MOC2 (Fig 3E). 
As measured by TUNEL assay, PD901 alone (MOC1) 
or in combination with rapamycin (MOC2) significantly 
induced apoptosis in tumor cells. These results suggest 
that despite both drugs demonstrating on-target signaling 
alterations, MEK but not mTOR inhibition consistently 
reduces tumor cell proliferation and induces tumor cell 
apoptosis in MOC tumors in vivo.
MEK but not mTOR inhibition consistently 
alters tumor vascularity and expression 
of angiogenic cytokines in the tumor 
microenvironment
Consistent with their external appearance following 
resection (Fig 2A), baseline vascularity was higher in 
MOC2 compared to MOC1 (Fig 4A, CD31 flow cytometry 
and immunostaining). Treatment with PD901 but not 
rapamycin consistently and significantly reduced MOC2 
tumor vascularity. Since a subset of CD31 cells in the 
tumors are also CD45+ and represent immature myeloid 
cells and not mature vascular cells, CD31 immunostaining 
was performed and revealed a pattern of intense mature 
vascularization in MOC2 tumors as measured by vessel 
count per HPF that was differentially altered by rapamycin 
and PD901 treatment. To determine if alterations in tumor 
vascularity correlated with changes in expression of 
angiogenic cytokines, RNA and protein levels of CXCL1 
and VEGF were measured from MOC tumor lysates 
(Fig  4B, 4C). While baseline protein levels of VEGF 
were similar between MOC tumors, baseline CXCL1 was 
significantly higher in the MOC2 tumor microenvironment 
(p < 0.001). Treatment with PD901 reduced VEGF in both 
MOC1 and MOC2 tumors, but rapamycin led to reduced 
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VEGF in MOC2 tumors only. Lower baseline CXCL1 
expression in MOC1 tumors was largely unaffected 
by either drug. Conversely, higher baseline CXCL1 in 
MOC2 tumors was reduced modestly by rapamycin and 
significantly by PD901. Interestingly, while CXCL1 RNA 
and protein levels were congruent, significant differences 
between VEGF RNA and proteins levels suggests a greater 
degree of post-transcriptional regulation of VEGF in MOC 
tumors. Further, cytokine measurements from MOC tumor 
lysates and from MOC cells in vitro differ significantly and 
suggest stromal or other microenvironment contributions 
to cytokine levels in vivo. Again, MEK but not mTOR 
inhibition results in consistently altered tumor vascularity 
and angiogenic cytokine/chemokine expression in 
MOC tumors. Cumulatively, the above experiments 
demonstrating altered tumor cell viability, proliferation, 
CD44 expression and MOC tumor vascularity and 
chemokine expression following MEK inhibition do not 
explain the durable treatment response observed in MOC1 
but not MOC2 tumors following withdrawal of mTOR 
inhibition.
Differences in baseline and effects of MEK 
and mTOR inhibition on the infiltration and 
activation of innate immune cell subsets in 
immunogenic and non-immunogenic  
MOC tumors
Given that mTOR inhibition results in durable 
primary tumor growth inhibition and prolonged 
survival of immunogenic MOC1 tumor bearing mice, 
yet does not appear to greatly alter MOC1 tumor 
cells directly, we hypothesized MEK and mTOR 
inhibition may differentially modulate the MOC tumor 
microenvironment. Following MOC1 and 2 transplantation 
into C57BL/6 mice, we assessed baseline differences 
Figure 3: In vivo on-target effects of MEK and mTOR inhibition in MOC tumors. Representative photomicrographs (20x) 
of immunohistochemical analysis of tumor sections from MOC1 and MOC2 tumors following 21 days of treatment with rapamycin and 
PD901 for A. S6K (S240/244), B. ERK1/2 (T202/Y204). C. flow cytometric analysis of cell surface CD44 expression on MOC1 and 
MOC2 tumors after treatment. Left y-axis represents % of tumor cells positive for CD44, right y-axis represents tumor cell CD44 mean 
fluorescence intensity (MFI). Significantly increased ERK1/2 phosphorylation and CD44 expression following rapamycin treatment alone 
in MOC2 tumors was reversed with combination treatment (B, C). D. analysis of proliferation of tumors cells following treatment via 
immunohistochemistry for Ki67. E. analysis of apoptosis of tumors cells following treatment via TUNEL assay. Shown are representative 
photomicrographs from MOC1 tumors. All stained section scoring was automated via Aperio ImageScope software analysis of ten 20x 
fields per section. Validation of the location of tumor cell nests and specific antibody staining was performed via pan-cytokeratin and 
isotype control staining, respectively, for each tumor and treatment condition (Supplementary Fig 2). *p < 0.05, **p < 0.01, ***p < 0.001 
for all experiments, analysis via one-way ANOVA with reference to untreated (control) tumors.
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and alterations in tumor immune infiltration following 
treatment via flow cytometry. Whereas Gr1+CD11b+ 
immature myeloid derived suppressor cells (MDSCs) 
can mediate T-cell immunosuppression [21], subsets of 
mature F4/80+ tumor-associated macrophages (TAMs) 
can mediate anti-tumor immunity [22]. Systemically, 
MOC tumor-bearing mice demonstrated significantly 
higher accumulation of splenic MDSCs compared 
to non-tumor bearing mice, and this splenic MDSC 
accumulation did not change with PD901 or rapamycin 
treatment (Supplementary Fig S3). MOC2 tumors 
demonstrated significantly higher baseline MDSC 
recruitment than MOC1 tumors (p < 0.001, Fig 5A, 
gating strategy Supplementary Fig S4A). High baseline 
MDSC accumulation in MOC2 was reduced significantly 
following combination therapy but not with either PD901 
or rapamycin alone. In MOC1 tumors, low baseline 
MDSC accumulation was reduced with rapamycin or 
PD901 alone or in combination.
In contrast to MDSCs, mature tumor-infiltrating 
macrophages were significantly higher in MOC1 than 
MOC2 (p < 0.001, Fig 5B, gating strategy Supplementary 
Fig S4B). Treatment with PD901 but not rapamycin 
significantly reduced accumulation of TAMs in MOC1 
tumors, whereas low baseline TAM accumulation in 
MOC2 tumors did not change. We further characterized 
TAMs as tumor-suppressing M1 or tumor-promoting M2 
phenotypes based upon cell surface MHC class II and 
CD206 expression (Supplementary Fig S4B). Evaluated 
as a ratio of M1:M2, MOC1 TAMs are a predominantly 
Figure 4: Variable alteration of in vivo tumor vascularity and angiogenic cytokine expression following MEK and 
mTOR inhibition. A. flow cytometric analysis of CD45-CD31+ cells in MOC1 and MOC2 tumors along with representative 20x 
photomicrographs of MOC1 and MOC2 tumor CD31 IHC to visually assess CD31+ blood vessels. Mean vessel counts were calculated 
from eight 20x HPFs per tumor and treatment condition. Isotype control staining confirmed specific CD31 antibody staining. Expression of 
CD31 on MOC1 and MOC2 tumor cells was ruled out at the protein level in vitro with flow cytometry (data not shown). B. quantification 
of angiogenic cytokine RNA from MOC1 and MOC2 tumor lysates via RTPCR. C. quantification of angiogenic cytokine protein from 
MOC1 and MOC2 tumor lysates via ELISA. For RTPCR and ELISA, three separate tumors from each tumor and each treatment condition 
were assessed in technical triplicate. *p < 0.05, **p < 0.01, ***p < 0.001 for all experiments, analysis via one-way ANOVA with reference 
to untreated (control) tumors.
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Figure 5: MEK and mTOR inhibition variably alter myeloid cell tumor infiltration and phenotype. Flow cytometric 
analysis of tumor infiltrating myeloid cells in MOC1 and MOC2 tumors. Dead cells excluded via 7AAD staining in all experiments. Each 
data point represents a separate tumor and reported values are per 1 × 105 total collected cells. A. infiltration of CD45+Gr1+CD11b+ 
MDSCs in rapamycin and PD901 treated tumors. B. infiltration of CD45+CD11b+Ly6ClowF4/80+ macrophages in rapamycin and PD901 
treated tumors. C. CD45+CD11b+Ly6ClowF4/80+ macrophages were phenotyped by cell surface MHC class II expression (and CD206 
surface expression, see Suppl Fig 4B). We classified M1s as MHC Class II high and M2s as MHC Class II low. Changes in the M1/M2 ratio 
following treatment with rapamycin and PD901 are shown. Tissues used for analysis are from one in vivo experiment in MOC1 and two 
independent experiments in MOC2. *p < 0.05, **p < 0.01, ***p < 0.001 for all experiments, analysis via one-way ANOVA with reference 
to untreated (control) tumors.
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M1 and MOC2 TAMs are a predominantly M2 phenotype 
(Fig 5C). PD901 reversed TAM phenotype in MOC1 
tumors with a shift from M1 to M2 phenotype and 
reduced recruitment of M2 TAMs in MOC2 tumors, 
leading to a M1:M2 ratio reversal from baseline in 
both tumors. Rapamycin treatment altered the M1:M2 
ratio in MOC1 tumors as well but did not significantly 
alter the MOC2 tumor M1:M2 ratio. Thus, while 
PD901 reduced macrophage infiltration and skewed 
macrophages toward the M2 phenotype in MOC1 tumors, 
it increased the M1:M2 TAM ratio and reduced MDSC 
accumulation when combined with rapamycin in MOC2 
tumors. Together, these data are interesting, but do not 
convincingly provide a mechanism for mTOR inhibition 
induced durable MOC1 tumor control.
Differences in baseline and effects of PD901 and 
rapamycin on the infiltration and activation 
of T-cell subsets in immunogenic and non-
immunogenic MOC tumors
We next hypothesized that MEK and mTOR 
inhibition may exert different effects on the development 
of adaptive immunity within the MOC tumor 
microenvironment. We systematically evaluated the 
infiltration and activation status of specific T-cell subsets 
(gating strategy Supplementary Fig 5A) following MEK 
and mTOR inhibition. Systemic (splenic) T-cells levels 
were not significantly altered with any treatment (Fig 6A). 
However, PD901 consistently induced a reduction in the 
number of infiltrating CD3+ T-cells in MOC1 and MOC2 
tumors (Fig 6B). At baseline, an even mix of CD4 and 
CD8 T-cells infiltrate into MOC1 tumors (Fig 6C, 6D). 
While similar numbers of CD3+ T-cells infiltrate MOC2 
tumors, these are nearly exclusively CD4 with very few 
infiltrating CD8 cells. In both tumors, CD4 cells were 
reduced following PD901 treatment in a similar pattern 
to CD3 cells. For CD8 cells, PD901 significantly reduced 
CD8 cell infiltration into MOC1 tumors (Fig 6D). 
Rapamycin trended toward the same effect but did not 
reach statistical significance. Neither drug enhanced 
CD8 cell recruitment into MOC2 tumors. As a measure 
of CD8 cell activation, we measured cell surface PD-1 
expression and found that rapamycin and PD901 alone 
or in combination significantly induced PD-1 expression 
on MOC1 infiltrating CD8 cells. This enhanced PD1 
expression was not seen on splenic CD8 cells following 
treatment (Supplementary Fig 5B), suggesting an 
enhanced degree of CD8 antigen exposure within the 
MOC1 tumor microenvironment [23].
To evaluate the functional effects on tumor specific 
immunity, we examined specific CD8+ responses to the 
tumor-associated antigen and endogenous retroviral 
envelope protein p15E that is known to harbor an 
H-2Kb-restricted antigenic epitope (KSPWFTTL) and is 
expressed in MOC cells. To evaluate changes in p15E 
antigen specific CD8 T-cells, an H-2Kb:KSPWFTTL 
tetramer was used to stain for p15E specific CD8 
T-cells [24, 25]. Baseline tetramer positivity of splenic 
CD8 cells was higher in MOC1 than MOC2 (Fig 6E), 
indicating more CD8 T-cell exposure to p15E antigen in 
MOC1 tumor bearing mice. Treatment with rapamycin 
or PD901 alone tended to increase the number of p15E-
specific T-cells without affecting the overall percentage 
of CD8 cells in the spleen (Supplementary Fig 5C), and 
this reached significance with combination therapy in 
mice bearing both MOC1 and 2 tumors indicating that 
targeted therapy was enhancing exposure to antigen and 
expansion of antigen-specific CD8 T-cells. Despite this 
systemic effect, PD901 but not rapamycin reduced tumor 
infiltration of p15E-specific CD8 cells in MOC1 tumors 
and neither drug induced accumulation of p15E-specific 
CD8 cells into MOC2 tumors (Fig 6F). Using CD107a 
expression as a specific marker of activation/degranulation 
in antigen specific CD8 cells in MOC1 tumors [26], 
staining suggested a high degree of tetramer+ CD8 cell 
activation at baseline within tumors that was not observed 
in tetramer+ splenocytes from MOC1 tumor-bearing mice 
(Supplementary Fig 5D). MEK but not mTOR inhibition 
significantly reduced CD107a staining of infiltrating p15E-
specific CD8 cells in MOC1 tumors indicating inhibition 
of antigen-specific CD8 T-cell degranulation following 
MEK inhibition.
For completeness, we examined for the presence of 
CD4+FoxP3+ Treg cells in both models (Supplementary 
Fig S6). Consistent with differences in their immunogenic 
phenotypes, MOC1 tumors exhibited a lower baseline 
level of Tregs compared to MOC2 tumors. Rapamycin 
modestly increased the number of infiltrating FoxP3+ 
CD4 cells. Alternatively, PD901 decreased FoxP3+ CD4 
cells in MOC2 tumors. Interestingly, 20–30% of FoxP3+ 
CD4 cells in both tumors were CD25+ (compared with 
70–80% of all splenic CD4+FoxP3+ Tregs), indicating 
that the majority of Tregs in MOC tumors are induced 
and not of thymic origin [27]. Treg CD25 cell surface 
expression was substantially reduced following rapamycin 
or PD901 treatment.
Cumulatively, these data suggest that MEK 
inhibition significantly inhibits the presence and 
activation status of T-cells in MOC tumors. In the case of 
MOC1, these effects tend to be detrimental with reduced 
infiltration of both total and antigen-specific CD8 cells 
as well as reduced antigen-specific degranulation of 
antigen-specific CD8 cells as measured by CD107a cell 
surface expression. Thus, mTOR inhibition appears to 
preserve while MEK inhibition appears to inhibit antigen-
specific T-cell responses in immunogenic MOC1 tumors, 
potentially explaining the durable responses observed 
following mTOR but not MEK inhibition in immunogenic 
MOC1 tumor bearing mice.
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MEK inhibition significantly suppresses CD3/28 
activated CD4 and CD8 T-cell expansion  
and function
Based on the above in vivo data suggesting that 
MEK inhibition potentially reduces the number and 
activation status of T-cells within the MOC tumor 
microenvironment, we experimentally measured the 
effect of MEK and mTOR inhibition on T-cells in vitro. 
At in vitro doses of drug well within those achieved 
in serum with treatment in mice and humans, MEK 
inhibition more significantly reduces CD4 and CD8 T-cell 
proliferation following physiologic stimulation with 
CD3/28 microbeads (Fig 7A). Similarly, IFNγ production 
and expression of activation and antigen-exposure markers 
CD69 and CD44 were significantly suppressed following 
T-cell activation in the presence of MEK but not mTOR 
inhibition (Fig 7B–7D). These data support our in vivo 
findings in immunogenic MOC1 tumors and indicate that, 
whereas MEK inhibition significantly suppresses T-cell 
expansion and function, mTOR inhibition relatively 
preserves it.
Primary tumor growth inhibition following 
mTOR inhibition in immunogenic MOC1 
tumors is CD8+ cell dependent
Given the lack of direct cytotoxic effects of 
mTOR inhibition on MOC1 cells, yet the durable tumor 
control following cessation of treatment and measured 
preservation of antigen-specific T-cell responses in 
MOC1 treated tumors, we hypothesized that the primary 
mechanism of rapamycin-induced growth delay was 
related to tumor immunity. To test this, we treated MOC1 
tumor bearing mice with the same rapamycin protocol 
with and without antibody-based systemic CD8 cell 
depletion. Fig 8A demonstrates that the primary growth 
inhibition of MOC1 tumors with mTOR inhibition is 
nearly completely abrogated with CD8 cell depletion 
compared to isotype control. Validation of complete 
Figure 6: MEK and mTOR inhibition variably alter systemic and tumor-infiltrating lymphocytes. Flow cytometric 
analysis of tumor infiltrating myeloid cells in MOC1 and MOC2 tumors. Dead cells excluded via 7AAD staining in all experiments. Each 
data point represents a separate tumor and reported values are per 1 × 105 total collected cells. A. CD3 cells in the spleens of MOC1 and 
MOC2 tumor-bearing mice treated with rapamycin and PD901. B. infiltration of CD45+CD3+ cells into treated MOC1 and MOC2 tumors. 
C. infiltration of CD45+CD3+CD4+ cells into treated MOC1 and MOC2 tumors. D. infiltration of CD45+CD3+CD8+ cells into treated 
MOC1 and MOC2 tumors, along with MOC1 tumor-infiltrating CD8 cell surface PD1 expression. E. % positivity of CD8+ splenocytes 
specific for an H2Kb-restricted p15E antigen (KSPWFTTL) in MOC1 and MOC2 tumor-bearing mice via tetramer staining. F. infiltration 
of CD45+CD3+CD8+tetramer+ cells into treated MOC1 and MOC2 tumors, along with CD107a staining on these tumor-infiltrating 
tetramer+CD8+ cells as a measure of activation and degranulation. Tissues used for analysis are from one in vivo experiment in MOC1 
and two experiments in MOC2. *p < 0.05, **p < 0.01, ***p < 0.001 for all experiments, analysis via one-way ANOVA with reference to 
untreated (control) tumors.
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Figure 7: Effects of MEK and mTOR inhibition on the proliferation and activation of stimulated T-cells. Flow cytometric 
analysis of sorted T-cells. A. CFSE labeled T-cells were stimulated with CD3/28 microbeads for 7 days in the presence of control or drug 
at the doses indicated. Representative histograms illustrating unstimulated (grey) and stimulated (blue) patterns of CFSE intensity on the 
left, with quantification of % inhibition relative to the maximum percentage of CFSE+ cells that move out of the parent population with 
CD3/28 stimulation alone using the formula [(expt – spon)/(max – spon)] on the right. B. representative dot plots of CD8 T-cells expressing 
IFNγ in response to CD3/28 stimulation with and without drug on the left, calculated % inhibition of the maximum percentage of IFNγ 
expressing cells with CD3/28 stimulation alone on the right. C. and D. representative histograms demonstrating CD69 and CD44 expression, 
respectively, on the surface of T-cells in response to CD3/28 stimulation with and without drug on the left, calculated % inhibition of the 
maximum MFI for each marker with CD3/28 stimulation alone on the right. Experiments were replicated three times. *p < 0.05, **p < 0.01, 
***p < 0.001 for all experiments, analysis via one-way ANOVA with reference to the inhibition of the % maximum for each experiment.
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Figure 8: Abrogation of MOC1 tumor growth inhibition following mTOR inhibition with systemic CD8 cell 
depletion. A. MOC1 cells were transplanted and allowed to form tumors with a volume of 0.1 cm3. Depletion of CD8 cells with 200 μg 
anti-CD8 antibody IP twice weekly was started one day before initiation of mTOR inhibition with rapamycin. Injection of a non-specific 
isotype antibody served as control. B. At the completion of the experiment, spleen and tumor tissues were harvest and flow cytometry 
performed to validate the depletion of CD8 cells both peripherally and in the tumor. Representative dot plots of spleen (top panels) and 
tumor tissue (bottom panels) are shown.
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systemic and intra-tumoral CD8 T-cell depletion is shown 
in Fig 8B. This data strongly suggests that the primary 
tumor growth inhibition and subsequent durable tumor 
control and improved survival in MOC1 tumor bearing 
mice following rapamycin treatment is due to preserved 
CD8 T-cell responses, whereas the lack of such responses 
following PD901 treatment is due to MEK-induced 
inhibition of adaptive immunity.
DISCUSSION
Here, we utilize newly described syngeneic MOC 
models of murine oral cavity cancer [20] to demonstrate 
differential effects of the mTOR inhibitor rapamycin and 
the MEK1/2 inhibitor PD901 alone or in combination on 
oncogenic signaling, tumor responses and survival and 
immune modulation in highly immunogenic (MOC1) 
and poorly immunogenic (MOC2) tumors. MEK but not 
mTOR inhibition in vitro induced cytotoxicity, reduced 
inflammatory cytokine secretion and CD44 expression 
and reduced migratory capacity in MOC1 and MOC2 
cells, consistent with the Ras-driver mutations shared 
by these carcinomas. Remarkably, different effects of 
these drugs were observed in MOC derived tumors 
in vivo. Both drugs alone or in combination significantly 
inhibited primary tumor growth, indicating a role for 
targeting MAPK and/or PI3K/mTOR signaling in vivo. 
Consistent with direct anti-proliferative and cytotoxic 
effects observed in vitro, MEK inhibition suppressed 
growth during the 21 days of treatment, but withdrawal 
led to rapid rebound of primary tumor growth and minimal 
improvement in survival in both MOC1 and MOC2 tumor-
bearing mice. While mTOR inhibition had limited effects 
in vitro, rapamycin potently inhibited tumor growth in vivo 
and subsequent drug withdrawal after 21 days of treatment 
was followed by a more durable response in a significant 
subset of tumor bearing mice with resulting prolonged 
survival compared to MEK inhibition. This treatment 
durability after withdrawal of therapy and survival effect 
of mTOR inhibition relative to MEK inhibition appeared 
to be more pronounced in immunogenic MOC1 tumor 
bearing mice compared to MOC2 tumor bearing mice.
Several observations from this and prior studies 
support the hypothesis that the enhanced durability of 
primary tumor control and prolonged survival in rapamycin 
treated MOC1 tumors could be due to differences in basal 
and drug effects on tumor microenvironment immune 
infiltration and/or activation. This differential effect did 
not appear to be due to enhanced in vivo inhibition of 
phospho-targets, reduced cell surface CD44 expression 
(known to correlate with MOC cell aggressiveness 
[20]), reduced tumor cell proliferation, reduced tumor 
vascularization or expression of angiogenic cytokines or 
enhanced tumor cell apoptosis, all of which were similarly 
or more significantly altered by MEK inhibition. The use 
of a syngeneic model allowed assessment of the infiltration 
and functional status of cells of innate and adaptive 
immunity that is limited in immunodeficient models. 
Treatment with PD901 alone or in combination was not 
associated with durable survival in immunogenic MOC1 
tumors. PD901 inhibited tumor infiltration of mature 
macrophages and reversed TAM polarization toward an 
M2 phenotype in MOC1 tumors. Mature macrophages 
producing TNF may be important in the inhibition of 
immunogenic tumors such as MOC1 [28]. Importantly, 
PD901 treatment appeared to inhibit total CD4 and CD8 
T-cell and antigen-specific CD8 T-cell infiltration into 
MOC1 tumors as well as antigen-specific T-cell activation/
degranulation as assessed by CD107a cell surface staining. 
In response to these results, we experimentally measured 
the relative suppression of activated T-cell expansion and 
activation, as measured by IFNγ secretion and CD69/
CD44 expression, and found potent suppression following 
MEK inhibition. Thus, blockade of adaptive T-cell 
responses and functional immunity following PD901 
treatment provide a mechanistic explanation for the rapid 
rebound of primary tumor growth in MOC1 tumor bearing 
mice following cessation of treatment. To validate that 
the primary mechanism of rapamycin-induced MOC1 
primary tumor growth inhibition was immunogenic, 
given the lack of measurable alteration in MOC1 cancer 
cell function, we depleted CD8 Cells in MOC1 tumor 
bearing mice and found that this essentially completely 
abrogated the growth inhibitory effects of rapamycin. 
To our knowledge, this study is the first to demonstrate 
a primarily immune-dependent mechanism of rapamycin-
induced tumor growth inhibition. In MOC2 tumors, 
which have very high immunosuppressive myeloid and 
lymphoid immune infiltration at baseline, several desirable 
changes were observed including reduced MDSC 
accumulation with combination therapy and a skewing of 
TAMs toward an M1 phenotype and reduced Treg tumor 
infiltration following MEK inhibition. However, we were 
unable to induce an adaptive response (recruitment of 
CD8 T-cells) within the tumor with either drug despite 
apparent enhancement of systemic antigen-specific CD8 
T-cells. Investigations into how to best enhance the 
immunogenicity of MOC2 tumors are underway.
Signaling through the MAPK pathway is known 
to be critical to T-cell function [9, 29], and our findings 
support the work of others demonstrating blockade of 
T-cell proliferation, cytokine expression and antigen-
specific expansion in vitro and in vivo following MEK 
but not Raf inhibition [30, 31] that may be model 
dependent. Our data strongly supports the need for 
further investigation into the effects of MEK inhibition 
in immunogenic tumors, where blockade of T-cell 
function may abrogate an existing anti-tumor immune 
response. Similarly, despite that rapamycin is used for 
immunosuppression following solid organ transplantation, 
rapamycin has shown anti-tumor activity in a variety of 
solid tumor types [32]. Rapamycin enhances development 
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of memory T-cell populations, perhaps at the expense 
of effector populations, and induces development of 
FoxP3+ Tregs [33–35]. These findings with ours support 
the context dependent immunosuppressive properties 
of rapamycin. Together with evidence that combination 
mTOR and MEK blockade enhanced on-treatment 
growth suppression of non-immunogenic MOC2 tumors, 
our findings of altered tumor immunity following MEK 
inhibition and preserved immunity following mTOR 
inhibition in immunogenic MOC1 tumors suggests the 
need for individual patient anti-cancer therapies to be 
tailored not only to identified oncogenic pathways but 
also to the immune status of the tumor. Patients with 
immunogenic tumors may benefit more from therapies 
that preserve existing anti-tumor immune responses, 
especially when combined with an immunotherapy such as 
a tumor vaccines or checkpoint inhibitor. Approximately 
50–70% of patients with HNSCCs harbor immunogenic 
tumors as defined by CD8 T-cell tumor infiltration [13], a 
lymphocyte “active” signature [3], and PD-L1 expression 
[12] and would be modeled by MOC1 tumors. Conversely, 
poorly immunogenic tumors may be modeled by MOC2 
tumors, for which the relative paucity of antigenic 
genomic alterations and high degree of local immune 
suppression may limit the effectiveness of immune-
stimulating therapies.
For poorly-immunogenic tumors such as MOC2, 
with genomic alterations co-activating MAPK and 
PI3K/mTOR pathways, combination MEK and mTOR 
inhibition maybe needed. Compensatory MAPK 
pathway activation and CD44 cell surface expression 
following mTOR inhibition alone was observed both 
in vitro and in vivo in MOC2 cells and tumors. This 
was reversed with combination therapy and may 
explain in part why combination treatment was needed 
to effectively suppress on-treatment primary tumor 
growth in MOC2 tumors. The concept of co-activated 
signaling pathway enhancement as a mechanism of 
targeted therapy resistance is well documented, and 
our data validates the principle of using combination 
therapy to block compensatory signaling through non-
targeted but co-activated oncogenic pathways [5, 36]. 
The combination of rapamycin and PD901 was well 
tolerated in this model with no appreciable weight loss 
or significant side effects from treatment.
Several limitations to our study exist. First, cell 
lines in the MOC model are RAS mutant and PIK3CA 
wild-type, similar to only a small subset of human 
HNSCC [3]. However, growth factor receptors and Ras 
activate PI3K, and this model exhibits co-activation of 
both PI3K/mTOR and MAPK pathways similar to the 
majority of human HNSCC. Indeed, the overall genomic 
landscape between MOC tumors and human HNSCC 
is highly conserved [37]. Additionally, we observed 
durable, immune-based responses following mTOR 
inhibition in MOC tumors in vivo despite the fact that 
they are Ras mutant. Next, tumor tissue used for the 
immune analyses were studied after prolonged treatment, 
and it is possible that the immune profile of MOC tumors 
is different in earlier stages of tumor progression and 
treatment. Additionally, mTOR and MEK inhibition may 
alter the interaction between tumor and other immune 
or stromal cells, such as cancer-associated fibroblasts, 
that were not evaluated here. These models may enable 
further experiments exploring different mechanisms of 
immune activation or suppression following treatment 
with different therapies, which are ongoing in our 
laboratory.
In summary, this study demonstrates the utility 
of the mTOR inhibitor rapamycin and the MEK1/2 
inhibitor PD901 in syngeneic models of oral cavity 
cancer. Not only do we validate the on-target effects 
of each drug both in vitro and in vivo, we demonstrate 
different mechanisms of primary tumor growth control 
between immunogenic MOC1 and poorly immunogenic 
MOC2 tumors. We experimentally show that MEK 
inhibition inhibits but mTOR inhibition relatively 
preserves anti-tumor T-cell responses both via tetramer-
based flow cytometry in MOC1 tumor tissue and in 
an in vitro T-cell proliferation and activation assay. 
Our finding that mTOR inhibition leads to a CD8 
cell dependent anti-tumor response in RAS-mutant, 
immunogenic MOC1 tumors is novel and suggests that 
mTOR targeting therapies may be useful in multiple 
tumor types regardless of underlying driver mutations. 
Further, these results have significant implications for 
future clinical trial planning involving combinations of 
these targeted therapies, as well as highlight the need 
for enhanced understanding of how different anti-cancer 
therapies alter tumor immunity to allow the rational 
design of anti-cancer and immunotherapy combinations.
MATERIALS AND METHODS
Cell lines
Murine Oral Cancer (MOC) cells were generated 
and maintained in culture in complete media as described 
previously [11, 20]. Treatment of MOC cells with 
pharmaceutical grade rapamycin (LC Labs, Woburn MA) 
and PD0325901 (PD901, SelleckChem, Houston, TX) was 
performed as indicated.
XTT assays
MOC1 and MOC2 cells were seeded at 103 cells/
well (96-well plate) in DMEM with 10% heat-inactivated 
fetal calf serum and 1% penicillin-streptomycin. After 
24 hours, cells were treated with varying concentrations 
of drug or vehicle and assessed for alteration in 




MOC cell lines were grown in 10 cm culture 
plates and treated with control or drug at the indicated 
concentrations for 48 hours. Following lysis, total protein 
levels were measured and blotting was performed using 
standard technique with actin control. All antibodies 




MOC1 and MOC2 cells were seeded at 105 cells/
well (6-well plate) in complete media. After 24 hours, 
cells were treated with varying concentrations of drug 
or vehicle as indicated. ELISA kits were purchased 
from R&D Systems (Minneapolis, MN) and used per 
manufacturer’s protocol. Reported cytokine expression 
levels were normalized for viable cell count.
In vivo
Approximately 20 mg of snap frozen tissue was 
lysed in the presence of protease and phosphatase 
inhibitors on the Qiagen TissueLyser II (30 Hz × 
2 min) with stainless steel disruption beads. Following 
determination of total protein levels, samples were diluted 
to standardized concentrations and ELISA kits were used 
as above.
Wounding assay
MOC1 and MOC2 cells were seeded at 105 cells/
well (6-well plate) in complete media, allowed to reach 
90% confluence, and pipette tips were used to generate 
perpendicular linear cell free wounds. Time 0 pictures 
were taken immediately following the addition of treated 
media. For each treatment condition and time point, a 
total of 8 images were captured and cell-free area was 
quantified using ImageStudioLite software.
Mice and in vivo experiments
Experiments were carried out using 8–10 week old 
female C57BL/6 mice purchased from the National Cancer 
Institute (NCI) Animal Production Facility in Frederick, 
MD. All animal studies were approved by the National 
Institute of Deafness and Other Communication Disorders 
Animal Care and Use Committee (ASP1364–14). To 
generate tumors, 1 × 106 MOC1 or 1 × 105 MOC2 cells 
were transplanted subcutaneously in the right flank. 
Tumors were allowed to engraft and reach a size of 
0.1 cm3 before treatment. Mice treated with rapamycin 
were administered a loading dose of 4.5 mg/kg via 
intraperitoneal (IP) injection, followed by 1.5 mg/kg via 
IP injection every other day for 21 days. Mice treated 
with PD901 were administered 1.5 mg/kg via oral gavage 
(OG) daily for 21 days. Control mice were treated with 
drug carriers alone (2% ethanol, 5.2% tween 80 and 5.2% 
PEG 400 in water for rapamycin and 0.5% HPMC and 
0.2% tween 80 in water for PD901). Following 21 days 
of therapy, treated and control tumor-bearing mice were 
euthanized and tumors were surgically removed. Tumor 
tissue used for RT-PCR or ELISA was snap frozen, 
tissue used for immunohistochemistry was fixed with 4% 
formalin for 24 hours and stored in 70% ethanol until use, 
and tissue for flow cytometric analysis was used fresh. 
In some experiments, systemic CD8 cell depletion was 
performed via IP injection of 200 μg of anti-CD8 antibody 
(clone YTS169.4, BioXCell, Lebanon, NH) twice weekly.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tumors 
were sectioned (6 micron thickness) by a third party 
vendor (Histoserv, Germantown, MD). Sections were 
deparaffinized with Histoclear and rehydrated with 
an ethanol gradient. Following quench of endogenous 
peroxidase with diluted hydrogen peroxide, and blocking 
with serum of the species of the secondary antibody, 
primary antibodies at pre-titrated concentrations were 
incubated overnight at 4C. All primary antibodies with 
the exception of CD31 (Abcam, Cambridge, MA) and the 
isotype controls (Biolegend, San Diego, CA) were from 
Cell Signaling Technology. Following incubation for 
1 hour with a biotinylated secondary antibody, signal was 
amplified with an ABC kit per manufacturer’s protocol and 
colorimetric staining was developed with DAB (Vector 
Labs, Burlingame, CA). Washes between each step were 
performed with a PBS based wash solution. Developed 
samples were counterstained with Hematoxylin QS 
(Vector Labs, cat# H-3404) and coverslips were mounted 
with Permount. Whole slides were digitized for analysis 
using the Aperio ScanScope CS system and quantified 
using the Aperio ImageScope Viewer software’s positive 
pixel count v9 algorithm or nuclear staining algorithm. 
Pancytokeratin staining was performed on each tissue 
block to ensure differentiation of tumor and stromal tissue, 
and isotype control stains were performed with each assay 
to ensure specific antibody staining (Suppl Fig 2).
TUNEL
Formalin-fixed, paraffin-embedded tumor sections 
were stained via a standard TUNEL assay protocol using 
an alkaline phosphatase enzyme label and a fuchsin (red) 
substrate.
RTPCR
Tumor lysates were generated using the Tissue 
Lyser II and total RNA was purified using the RNEasy 
Mini Kit (Qiagen, Valencia, CA) per the manufacturer’s 
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protocol. cDNA was synthesized utilizing a High Capacity 
cDNA Reverse Transcription Kit (Life Technologies, 
Waltham, MA). Taqman Single Tube primers and a 
Universal PCR Master Mix (Life Technologies) were 
used to assess the relative expression of target genes 
in comparison to GAPDH on a Viia7 qPCR analyzer 
(Applied Biosystems, Carlsbad, CA).
Flow cytometry
In vitro
MOC cells were treated as indicated and passed 
through a 40 μM filter to generate a single cell suspension. 
Nonspecific binding was blocked using an anti-mouse 
CD16/32 antibody (Biolegend, San Diego, CA) and cells 
were stained with a flourophore-conjugated CD44 clone 
IM7 antibody. Washes between steps was performed with 
a 1% BSA in 1xPBS solution. Dead cells were excluded 
via 7AAD staining in all experiments.
In vivo
Following in vivo treatment as indicated, 
fresh tumor tissue was minced into 1 mm pieces and 
digested into a single suspension using the murine 
tumor dissociation kit from Miltenyi Biotech (Auburn, 
CA) per the manufacturer’s protocol. Both chemical 
and mechanical (gentleMACS, Miltenyi) dissociation 
techniques were utilized with consistent cell viability 
of 70% or greater. After filtering the tumor suspension 
through a 100 μM filter and several washes with a 
1% BSA in 1xPBS solution, cell surface staining was 
performed using flourophore conjugated anti-mouse 
CD45.2 clone 104, Gr1 clone RB6–8C5, Cd11b clone 
M1/70, Ly6C clone HK1.4, F4/80 clone BM8, I-A/I-E 
clone M5/114.15.2, CD206 clone C068C2, CD3 clone 
145–2C11, CD4 clone GK1.5, CD8 clone 53–6.7 or 
KT15, CD25 clone PC61, PD1 CLONE RMP1–30, 
CD107a clone 1D4B antibodies (Biolegend) as indicated. 
H2Kb:KSPWFTTL tetramer was purchased from MBL 
(Woburn, MA). Use of anti-CD8 antibody close KT15 
was required with tetramer staining sue to epitope 
compatibility, and specificity of tetramer staining was 
validates with KSPWFTTL peptide vaccination of naïve 
C57BL/6 mice (data not shown). Intracellular staining 
for FoxP3 in CD4+ T-lymphocytes was performed 
using the eBioscience (San Diego, CA) Treg staining 
kit #1 per manufacturer’s protocol. Specific staining 
of each antibody used was validated with the use of 
isotype control antibodies and a “fluorescence minus 
one” method of antibody combination validation. Dead 
cells were excluded with 7AAD staining if cell surface 
staining only and via LIVE/DEAD fixable viability dye 
staining (Life Technologies) for intracellular staining. 
Data was acquired on a FACSCanto using FACSDiva 
software (BD Biosciences, San Diego, CA) and analyzed 
on FlowJo software vX.0.7r2 (Ashland, OR).
In vitro T-cell assays
Murine splenocytes were sorted from whole spleens 
via magnetic separation using an “untouched” T-cell 
purification approach (autoMACS, Miltenyi). T-cells 
were incubated with CD3/CD28 coated microbeads 
(Mouse T-activator Dynabeads, Life Technologies) at a 
1:1 cell to bead ratio in complete T-cell media. For T-cell 
proliferation experiments, T-cells were labeled with 5 μM 
CSFE and incubated with CD3/28 microbeads for 7 days 
with either drug or control. Flow cytometry was then used 
to measure loss of CFSE signal in proliferating T-cells. For 
T-cell activation assays, sorted T-cells were incubated with 
CD3/28 microbeads for 24 hours, then flow cytometry-
based assays were performed to measure IFNγ release 
(PE-IFNγ capture assay, Miltenyi) or cell surface CD69 
and CD44 as detailed above.
Statistical analysis
Tests of significance between pairs of data are 
reported as p-values, derived using a student’s t-test with 
a two-tailed distribution and calculated at 95% confidence. 
Comparison of multiple sets of related data was achieved 
with one- or two-way analysis of variance (ANOVA). 
Survival curves compared using the log-rank (Mantel 
Cox) test. When present, error bars reflect standard error 
of measurement (SEM). Significance was set in each case 
to p < 0.05.
ACKNOWLEDGMENTS
We thank Drs. Paul Clavijo, James Hodge and 
Young Kim for their review and critique of this work and 
manuscript.
CONFLICTS OF INTEREST
None by any of the authors.
GRANT SUPPORT
This work was supported by the Intramural Program 
of NIDCD. HC was supported by through the National 
Institutes of Health (NIH) Medical Research Scholars 
Program, a public-private partnership supported jointly 
by the NIH and generous contributions to the Foundation 
for the NIH from Pfizer Inc, The Doris Duke Charitable 
Foundation, The Newport Foundation, The American 
Association for Dental Research, The Howard Hughes 
Medical Institute, and the Colgate-Palmolive Company, 
as well as other private donors.
Editorial note
This paper has been accepted based in part on peer-
review conducted by another journal and the authors’ 
Oncotarget36416www.impactjournals.com/oncotarget
response and revisions as well as expedited peer-review 
in Oncotarget.
REFERENCES
1. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, 
Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, 
Kim H, Axelrod R, Silverman CC, et al. Human papilloma-
virus and survival of patients with oropharyngeal cancer. 
New England Journal of Medicine. 2010; 363:24–35.
2. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, 
Cooper JS, Forastiere A, Ang KK. Factors associated with 
severe late toxicity after concurrent chemoradiation for 
locally advanced head and neck cancer: an RTOG analysis. 
Journal of Clinical Oncology. 2008; 26:3582–3589.
3. Cancer Genome Atlas Network . Comprehensive genomic 
characterization of head and neck squamous cell carcino-
mas. Nature. 2015; 517:576–582.
4. Broek RV, Mohan S, Eytan DF, Chen Z, Van Waes C. The 
PI3K/Akt/mTOR axis in head and neck cancer: functions, 
aberrations, crosstalk, and therapies. Oral Diseases. 2013; 
19:1–11.
5. Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, 
Diao L, Fan YH, Stemke-Hale K, Heymach JV, Myers JN, 
Glisson BS, Johnson FM. A comprehensive evaluation of 
biomarkers predictive of response to PI3K inhibitors and 
of resistance mechanisms in head and neck squamous 
cell carcinoma. Molecular Cancer Therapeutics. 2014; 
13:2738–2750.
6. Rampias T, Giagini A, Siolos S, Matsuzaki H, Sasaki C, 
Scorilas A, Psyrri A. RAS/PI3K crosstalk and cetuximab 
resistance in head and neck squamous cell carcinoma. 
Clinical Cancer Research. 2014; 20:2933–2946.
7. Toulany M, Minjgee M, Saki M, Holler M, Meier F, 
Eicheler W, Rodemann HP. ERK2-dependent reactivation 
of Akt mediates the limited response of tumor cells with 
constitutive K-RAS activity to PI3K inhibition. Cancer 
Biology & Therapy. 2014; 15:317–328.
8. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, 
Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, 
Kaiser B, Wick MJ, Alvarez C, Cavazos A, et al. The clini-
cal effect of the dual-targeting strategy involving PI3K/
AKT/mTOR and RAS/MEK/ERK pathways in patients 
with advanced cancer. Clinical Cancer Research. 2012; 
18:2316–2325.
9. Ott P, Adams S. Small-molecule protein kinase inhibitors 
and their effects on the immune system: implications for 
cancer treatment. Immunotherapy. 2011; 3:213–227.
10. Postow MA, Callahan MK, Wolchok JD. Immune 
Checkpoint Blockade in Cancer Therapy. Journal of 
Clinical Oncology. 2015; 33:1974–1982.
11. Judd NP, Allen CT, Winkler AE, Uppaluri R. Comparative 
analysis of tumor-infiltrating lymphocytes in a syngeneic 
mouse model of oral cancer. Otolaryngolology Head and 
Neck Surgery. 2012; 147:493–500.
12. Seiwert T.Y. A phase iB study of MK-3475 in patients with 
human papillomavirus (HPV)-associated and non-HPV-
associated head and neck (H/N) cancer, in ASCO. J Clin 
Oncol: Chicago, IL. 2014; .
13. Balermpas P, Rödel F, Weiss C, Rödel C, Fokas E. Tumor-
infiltrating lymphocytes favor the response to chemoradio-
therapy of head and neck cancer. Oncoimmunology. 2014; 
3:e27403.
14. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, 
Smith DC, McDermott DF, Powderly JD, Carvajal RD, 
Sosman JA, Atkins MB, Leming PD, Spigel DR, 
Antonia SJ, et al. Safety, activity, and immune correlates 
of anti-PD-1 antibody in cancer. New England Journal of 
Medicine. 2012; 366:2443–2454.
15. LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, 
Malburg L, Chapman PB, DePrimo SE, Bentivegna S, 
Wilner KD, Tan W, Ricart AD. Phase I pharmacokinetic 
and pharmacodynamic study of the oral MAPK/ERK kinase 
inhibitor PD-0325901 in patients with advanced cancers. 
Clinical Cancer Research. 2010; 16:1924–1937.
16. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 
Phosphorylation and regulation of Akt/PKB by the rictor-
mTOR complex. Science. 2005; 307:1098–1101.
17. Harrington LS, Findlay GM, Gray A, Tolkacheva T, 
Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, 
Shepherd PR, Gout I, Downes CP, Lamb RF. The TSC1–2 
tumor suppressor controls insulin-PI3K signaling via reg-
ulation of IRS proteins. Journal of Cell Biolology. 2004; 
166:213–223.
18. Young MR, Petruzzelli GJ, Kolesiak K, Achille N, 
Lathers DM, Gabrilovich DI. Human squamous cell carci-
nomas of the head and neck chemoattract immune suppres-
sive CD34(+) progenitor cells. Human Immunology. 2001; 
62:332–341.
19. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, 
Jackson S, Jackson C, Van Waes C. Effects of pharmaco-
logic antagonists of epidermal growth factor receptor, PI3K 
and MEK signal kinases on NF-kappaB and AP-1 activation 
and IL-8 and VEGF expression in human head and neck 
squamous cell carcinoma lines. International Journal of 
Cancer. 2002; 99:538–548.
20. Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, 
Law JH, Lewis JS Jr, Dunn GP, Bui JD, Sunwoo JB, 
Uppaluri R. ERK1/2 regulation of CD44 modulates oral 
cancer aggressiveness. Cancer Research. 2012; 72:365–374.
21. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor 
cells as regulators of the immune system. Nature Reviews 
Immunology. 2009; 9:162–174.
22. O’Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, 
Arthur C, White JM, Uppaluri R, Andrews DM, 
Ngiow SF, Teng MW, Smyth MJ, Schreiber RD, Bui JD. 
Oncotarget36417www.impactjournals.com/oncotarget
Cancer immunoediting by the innate immune system in the 
absence of adaptive immunity. Journal of Experimental 
Medicine. 2012; 209:1869–1882.
23. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, 
Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, 
Almeida JR, Darko S, et al. PD-1 identifies the patient-
specific CD8(+) tumor-reactive repertoire infiltrating 
human tumors. Journal of Clinical Investigation. 2014; 
124:2246–2259.
24. Yang JC, Perry-Lalley D. The envelope protein of an endog-
enous murine retrovirus is a tumor-associated T-cell antigen 
for multiple murine tumors. Journal of Immunotherapy. 
2000; 23:177–183.
25. Kudo-Saito C, Hodge JW, Kwak H, Kim-Schulze S, 
Schlom J, Kaufman HL. 4–1BB ligand enhances tumor-
specific immunity of poxvirus vaccines. Vaccine. 2006; 
24:4975–4986.
26. Betts MR, Brenchley JM, Price DA, De Rosa SC, 
Douek DC, Roederer M, Koup RA. Sensitive and via-
ble identification of antigen-specific CD8+ T cells by 
a flow cytometric assay for degranulation. Journal of 
Immunological Methods. 2003; 281:65–78.
27. elenay S, Lopes-Carvalho T, Caramalho I, Moraes-
Fontes MF, Rebelo M, Demengeot J. Foxp3+ CD25- CD4 
T cells constitute a reservoir of committed regulatory cells 
that regain CD25 expression upon homeostatic expansion. 
Proceedings of the National Academy of Sciences of the 
United States of America. 2005; 102:4091–4096.
28. Urban JL, Shepard HM, Rothstein JL, Sugarman BJ, 
Schreiber H. Tumor necrosis factor: a potent effector 
 molecule for tumor cell killing by activated macrophages. 
Proceedings of the National Academy of Sciiences of the 
United States of America. 1986; 83:5233–5237.
29. Ott PA, Bhardwaj N. Impact of MAPK Pathway Activation 
in BRAF(V600) Melanoma on T Cell and Dendritic Cell 
Function. Frontiers in Immunology. 2013; 4:346.
30. Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, 
Yang J, Seestaller-Wehr L, Zhang SY, Hopson C, 
Tsvetkov L, Jing J, Zhang S, et al. The BRAF, and MEK 
Inhibitors Dabrafenib and Trametinib: Effects on Immune 
Function and in Combination with Immunomodulatory 
Antibodies Targeting PD-1, PD-L1, and CTLA-4. Clinical 
Cancer Research. 2015; 21:1639–1651.
31. Vella LJ, Pasam A, Dimopoulos N, Andrews M, Knights A, 
Puaux AL, Louahed J, Chen W, Woods K, Cebon JS. MEK 
inhibition, alone or in combination with BRAF inhibition, 
affects multiple functions of isolated normal human lym-
phocytes and dendritic cells. Cancer Immunology Research. 
2014; 2:351–360.
32. Simpson DR, Mell LK, Cohen EE. Targeting the PI3K/
AKT/mTOR pathway in squamous cell carcinoma of the 
head and neck. Oral Oncology. 2015; 51:291–298.
33. Rao RR, Li Q, Odunsi K, Shrikant PA. The mTOR kinase 
determines effector versus memory CD8+ T cell fate by 
regulating the expression of transcription factors T-bet and 
Eomesodermin. Immunity. 2010; 32:67–78.
34. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, 
Bachmann MF, Larsen CP, Ahmed R. mTOR regu-
lates memory CD8 T-cell differentiation. Nature. 2009; 
460:108–112.
35. Wang Y, Sparwasser T, Figlin R, Kim HL. Foxp3+ T cells 
inhibit antitumor immune memory modulated by mTOR 
inhibition. Cancer Research. 2014; 74:2217–2228.
36. Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, 
Buscarino M, Ribero D, Muratore A, Massucco P, 
Pisacane A, Risio M, Capussotti L, Marsoni S, et al. 
Inhibition of MEK and PI3K/mTOR suppresses tumor 
growth but does not cause tumor regression in patient-
derived xenografts of RAS-mutant colorectal carcinomas. 
Clinical Cancer Research. 2012; 18:2515–2525.
37. Onken MD, Winkler AE, Kanchi KL, Chalivendra V, 
Law JH, Rickert CG, Kallogjeri D, Judd NP, Dunn GP, 
Piccirillo JF, Lewis JS Jr, Mardis ER, Uppaluri R. A sur-
prising cross-species conservation in the genomic landscape 
of mouse and human oral cancer identifies a transcriptional 
signature predicting metastatic disease. Clinical Cancer 
Research. 2014; 20:2873–2884.
